The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre

A. G. Singal, M. O. Rakoski, R. Salgia, S. Pelletier, T. H. Welling, R. J. Fontana, A. S. Lok, J. A. Marrero

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aliment Pharmacol Ther 31, 625-633 SummaryBackground The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined. Aim To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients. Methods Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed. Results In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95%CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95%CI 1.17-3.08) and stage of disease (HR 1.51, 95%CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95% CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma. Conclusions Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.

Original languageEnglish (US)
Pages (from-to)625-633
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume31
Issue number6
DOIs
StatePublished - Mar 2010

Fingerprint

Cholangiocarcinoma
Tertiary Care Centers
Survival
Bilirubin
Multivariate Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. / Singal, A. G.; Rakoski, M. O.; Salgia, R.; Pelletier, S.; Welling, T. H.; Fontana, R. J.; Lok, A. S.; Marrero, J. A.

In: Alimentary Pharmacology and Therapeutics, Vol. 31, No. 6, 03.2010, p. 625-633.

Research output: Contribution to journalArticle

Singal, A. G. ; Rakoski, M. O. ; Salgia, R. ; Pelletier, S. ; Welling, T. H. ; Fontana, R. J. ; Lok, A. S. ; Marrero, J. A. / The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. In: Alimentary Pharmacology and Therapeutics. 2010 ; Vol. 31, No. 6. pp. 625-633.
@article{b6a0f872b5b648eaaa7c500a1e3eee4c,
title = "The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre",
abstract = "Aliment Pharmacol Ther 31, 625-633 SummaryBackground The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined. Aim To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients. Methods Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed. Results In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95{\%}CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95{\%}CI 1.17-3.08) and stage of disease (HR 1.51, 95{\%}CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95{\%} CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma. Conclusions Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.",
author = "Singal, {A. G.} and Rakoski, {M. O.} and R. Salgia and S. Pelletier and Welling, {T. H.} and Fontana, {R. J.} and Lok, {A. S.} and Marrero, {J. A.}",
year = "2010",
month = "3",
doi = "10.1111/j.1365-2036.2009.04218.x",
language = "English (US)",
volume = "31",
pages = "625--633",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre

AU - Singal, A. G.

AU - Rakoski, M. O.

AU - Salgia, R.

AU - Pelletier, S.

AU - Welling, T. H.

AU - Fontana, R. J.

AU - Lok, A. S.

AU - Marrero, J. A.

PY - 2010/3

Y1 - 2010/3

N2 - Aliment Pharmacol Ther 31, 625-633 SummaryBackground The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined. Aim To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients. Methods Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed. Results In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95%CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95%CI 1.17-3.08) and stage of disease (HR 1.51, 95%CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95% CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma. Conclusions Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.

AB - Aliment Pharmacol Ther 31, 625-633 SummaryBackground The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined. Aim To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients. Methods Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed. Results In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95%CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95%CI 1.17-3.08) and stage of disease (HR 1.51, 95%CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95% CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma. Conclusions Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.

UR - http://www.scopus.com/inward/record.url?scp=76449111456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449111456&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.04218.x

DO - 10.1111/j.1365-2036.2009.04218.x

M3 - Article

C2 - 20003093

AN - SCOPUS:76449111456

VL - 31

SP - 625

EP - 633

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -